Department of Radiation Oncology, University Hospital Heidelberg, Im Neuenheimer Feld 400, Heidelberg 69120, Germany.
Radiat Oncol. 2013 Nov 6;8:260. doi: 10.1186/1748-717X-8-260.
Characterization of combination effects of chemotherapy drugs with carbon ions in comparison to photons in vitro.
The human colon adenocarcinoma cell line WiDr was tested for combinations with camptothecin, cisplatin, gemcitabine and paclitaxel. In addition three other human tumour cell lines (A549: lung, LN-229: glioblastoma, PANC-1: pancreas) were tested for the combination with camptothecin. Cells were irradiated with photon doses of 2, 4, 6 and 8 Gy or carbon ion doses of 0.5, 1, 2 and 3 Gy. Cell survival was assessed using the clonogenic growth assay. Treatment dependent changes in cell cycle distribution (up to 12 hours post-treatment) were measured by FACS analysis after propidium-iodide staining. Apoptosis was monitored for up to 36 hours post-treatment by Nicoletti-assay (with qualitative verification using DAPI staining).
All cell lines exhibited the well-known increase of killing efficacy per unit dose of carbon ion exposure, with relative biological efficiencies at 10% survival (RBE10) ranging from 2.3 to 3.7 for the different cell lines. In combination with chemotherapy additive toxicity was the prevailing effect. Only in combination with gemcitabine or cisplatin (WiDr) or camptothecin (all cell lines) the photon sensitivity was slightly enhanced, whereas purely independent toxicities were found with the carbon ion irradiation, in all cases. Radiation-induced cell cycle changes displayed the generally observed dose-dependent G2-arrest with little effect on S-phase fraction for all cell lines for photons and for carbon ions. Only paclitaxel showed a significant induction of apoptosis in WiDr cell line but independent of the used radiation quality.
Combined effects of different chemotherapeutics with photons or with carbon ions do neither display qualitative nor substantial quantitative differences. Small radiosensitizing effects, when observed with photons are decreased with carbon ions. The data support the idea that a radiochemotherapy with common drugs and carbon ion irradiation might be as feasible as respective photon-based protocols. The present data serve as an important radiobiological basis for further combination experiments, as well as clinical studies on combination treatments.
在体外比较化疗药物与碳离子联合作用的特点,以光子作为对照。
用人结肠腺癌细胞系 WiDr 检测与喜树碱、顺铂、吉西他滨和紫杉醇的联合作用。此外,还检测了另外三种人类肿瘤细胞系(A549:肺、LN-229:脑胶质瘤、PANC-1:胰腺)与喜树碱的联合作用。用光子剂量 2、4、6 和 8Gy 或碳离子剂量 0.5、1、2 和 3Gy 照射细胞。用集落形成生长试验评估细胞存活。用碘化丙啶染色后通过 FACS 分析测量处理依赖性的细胞周期分布变化(处理后达 12 小时)。用尼科莱蒂(Nicoletti)测定法监测处理后达 36 小时的凋亡(用 DAPI 染色进行定性验证)。
所有细胞系均表现出已知的碳离子暴露单位剂量杀伤效力增加,不同细胞系的相对生物效率(RBE10)在 10%存活时为 2.3 至 3.7。与化疗联合具有相加毒性。只有与吉西他滨或顺铂(WiDr)或喜树碱(所有细胞系)联合时,光子敏感性略有增强,而在所有情况下,单纯的碳离子照射均具有纯的独立毒性。辐射诱导的细胞周期变化显示出通常观察到的剂量依赖性 G2 期阻滞,所有细胞系的 S 期比例几乎没有影响,无论是用光子还是碳离子照射。只有紫杉醇在 WiDr 细胞系中引起明显的细胞凋亡诱导,但与所使用的射线质量无关。
不同化疗药物与光子或碳离子的联合作用既没有表现出定性的差异,也没有表现出实质性的定量差异。当观察到光子时,小的放射增敏作用会随着碳离子的使用而降低。这些数据支持这样一种观点,即使用普通药物进行放化疗并用碳离子照射与各自基于光子的方案一样可行。目前的数据为进一步的联合实验以及关于联合治疗的临床研究提供了重要的放射生物学基础。